Abstract
Background: The aim of this pilot study was to assess the potential of cystatin C (Cys C) as a biomarker in NHL and to explore its association with paraoxonase 1 (PON1) activity. Methods: The study included 44 patients with B-cell NHL and 44 healthy subjects. Cys C was measured using the Cobas e 801 analyzer (Roche Diagnostics GmbH, Mannheim, Germany), while PON1and TAS were measured on the ILab 300+ system (Instrumentation Laboratory, Milan, Italy).
Results: The serum level of Cys C (mg/L) was significantly higher in NHL patients compared to control subjects :1.03 (0.88–1.24) vs 0.83 (0.78–0.90), P <0.001. The diagnostic performance of Cys C, as assessed by the area under the ROC curve (AUC), was 0.812 (95% CI: 0.732–0.902). The optimal cut-off value for Cys C was 0.870 mg/L with a sensitivity and specificity of 77.1% and 75.6%, respectively. A significant negative correlation was observed between Cys C and PON1 activity (r = –0.42, P = 0.010) in NHL patients.
Conclusions: This study underscores the potential of Cys C as a biomarker in NHL. Notably, in the multivariable analysis, Cys C emerged as the only significant predictor of the disease, with each unit increase associated with an approximately threefold higher odds of NHL. Furthermore, the negative correlation between Cys C and PON1, identified for the first time in patients with NHL, may offer valuable insights for future research into the molecular mechanisms underlying this malignancy.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.